Regulatory approval

Published by the Health Canada.

Health Canada approved crizotinib for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

This is written in the approval document as:

XALKORI (crizotinib) is indicated for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

Citation

Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib